The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening.

T Lauritzen, S Griffin, K Borch-Johnsen, N J Wareham, B H Wolffenbuttel, G Rutten
{"title":"The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening.","authors":"T Lauritzen,&nbsp;S Griffin,&nbsp;K Borch-Johnsen,&nbsp;N J Wareham,&nbsp;B H Wolffenbuttel,&nbsp;G Rutten","doi":"10.1038/sj.ijo.0801420","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The overall aims of the ADDITION study are to evaluate whether screening for prevalent undiagnosed Type 2 diabetes is feasible, and whether subsequent optimised intensive treatment of diabetes, and associated risk factors, is feasible and beneficial.</p><p><strong>Design: </strong>Population-based screening in three European countries followed by an open, randomised controlled trial.</p><p><strong>Subjects and methods: </strong>People aged 40-69 y in the community, without known diabetes, will be offered a random capillary blood glucose screening test by their primary care physicians, followed, if equal to or greater than 5.5 mmol/l, by fasting and 2-h post-glucose-challenge blood glucose measurements. Three thousand newly diagnosed patients will subsequently receive conventional treatment (according to current national guidelines) or intensive multifactorial treatment (lifestyle advice, prescription of aspirin and ACE-inhibitors, in addition to protocol-driven tight control of blood glucose, blood pressure and cholesterol). Patients allocated to intensive treatment will be further randomised to centre-specific interventions to motivate adherence to lifestyle changes and medication. Duration of follow-up is planned for 5 y. Endpoints will include mortality, macrovascular and microvascular complications, patient health status and satisfaction, process-of-care indicators and costs.</p>","PeriodicalId":14227,"journal":{"name":"International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity","volume":"24 Suppl 3 ","pages":"S6-11"},"PeriodicalIF":0.0000,"publicationDate":"2000-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/sj.ijo.0801420","citationCount":"268","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/sj.ijo.0801420","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 268

Abstract

Objective: The overall aims of the ADDITION study are to evaluate whether screening for prevalent undiagnosed Type 2 diabetes is feasible, and whether subsequent optimised intensive treatment of diabetes, and associated risk factors, is feasible and beneficial.

Design: Population-based screening in three European countries followed by an open, randomised controlled trial.

Subjects and methods: People aged 40-69 y in the community, without known diabetes, will be offered a random capillary blood glucose screening test by their primary care physicians, followed, if equal to or greater than 5.5 mmol/l, by fasting and 2-h post-glucose-challenge blood glucose measurements. Three thousand newly diagnosed patients will subsequently receive conventional treatment (according to current national guidelines) or intensive multifactorial treatment (lifestyle advice, prescription of aspirin and ACE-inhibitors, in addition to protocol-driven tight control of blood glucose, blood pressure and cholesterol). Patients allocated to intensive treatment will be further randomised to centre-specific interventions to motivate adherence to lifestyle changes and medication. Duration of follow-up is planned for 5 y. Endpoints will include mortality, macrovascular and microvascular complications, patient health status and satisfaction, process-of-care indicators and costs.

add研究:对筛查出的2型糖尿病患者的发病率和死亡率进行强化多因素干预的成本-效果试验。
目的:add研究的总体目的是评估筛查普遍未确诊的2型糖尿病是否可行,以及随后对糖尿病及相关危险因素进行优化强化治疗是否可行和有益。设计:在三个欧洲国家进行基于人群的筛查,然后进行一项开放的随机对照试验。对象和方法:在社区中,年龄在40-69岁,没有已知糖尿病的人,将由他们的初级保健医生随机提供毛细血管血糖筛查试验,然后,如果等于或大于5.5 mmol/l,则进行空腹和2小时葡萄糖挑战后血糖测量。3000名新诊断的患者随后将接受常规治疗(根据目前的国家指南)或强化多因素治疗(生活方式建议、阿司匹林和ace抑制剂处方,以及严格控制血糖、血压和胆固醇)。分配到强化治疗的患者将进一步随机分配到中心特定的干预措施,以激励坚持改变生活方式和药物治疗。随访时间计划为5年。终点包括死亡率、大血管和微血管并发症、患者健康状况和满意度、护理过程指标和成本。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信